AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 25 - (NewsRx.com) -- Conceptus, Inc., announced that bilateral placement has been achieved in more than 400 patients in the pivotal clinical study of the STOP [TM] (Selective Tubal Occlusion Procedure) non-surgical permanent contraception device for women.
The pivotal study is designed to obtain 12-month effectiveness data on 400 patients with bilateral placement to support a Pre-Market Approval (PMA) application. Accordingly, the PMA application filing timeline is expected to be accelerated by approximately three months.
Enrollment in the multi-center, international pivotal clinical trial for STOP commenced in May of 2000. Additional patients will continued to be enrolled to replace any patients who may be lost-to-follow-up or who cannot be evaluated for other reasons. The pivotal trial will examine safety, effectiveness, and patient comfort during the placement procedure and subsequent use of the STOP device.
"The rapid enrollment we've experienced in the STOP trial highlights the desire women have for a new permanent contraceptive option, and demonstrates the tremendous commitment of the physicians and their staffs at all of the investigational sites," said Jay M. Cooper, MD, Women's Health Research Center, Phoenix, Arizona, and the principal U.S. investigator of STOP.
The pivotal study protocol requires 12 months of follow-up after each patient begins to ...
Source: HighBeam Research, Patient Enrollment Goal Met for Tubal Occlusion Trial.(Conceptus Inc....